GlassScriptPhysician profile
Kevin Wong
NPI 1649666421
$2,833.26
in general payments reported to CMS, 2019-2025
21 companies · $1,564 in 2025
The $1,564 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $390 · 2022: $17.96 · 2023: $679 · 2024: $182 · 2025: $1,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,564 · Food and Beverage: $861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,564.44 |
| Food and Beverage | $861.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Histosonics, INC. | $1,564.44 | 2025 | |
| Abbvie INC. | $181.59 | 2024 | |
| Myriad Genetic Laboratories, INC. | $173.10 | 2023 | Myrisk |
| Amgen INC. | $171.72 | 2021-2023 | Kyprolis, Lumakras |
| Acclarent, INC | $121.71 | 2021 | |
| Glaxosmithkline, LLC. | $98.15 | 2021-2023 | Shingrix |
| Janssen Pharmaceuticals, INC | $81.52 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $62.12 | 2023 | Imfinzi |
| Pfizer INC. | $55.49 | 2023 | |
| Mirati Therapeutics, INC. | $52.81 | 2023 | Krazati |
| Eisai INC. | $47.61 | 2023 | |
| Merck Sharp & Dohme LLC | $31.99 | 2023 | Keytruda |
| Incyte Corporation | $27.45 | 2023 | Pemazyre, Monjuvi |
| Medtronic, INC. | $25.79 | 2021 | |
| Kyowa Kirin, INC. | $24.72 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $21.19 | 2023 | Erleada |
| Array Biopharma INC | $19.32 | 2023 | Braftovi, Lorbrena |
| Jazz Pharmaceuticals INC. | $19.19 | 2023 | |
| Taiho Oncology, INC. | $18.55 | 2023 | |
| Baxter Healthcare | $17.96 | 2022 | |
| Stemline Therapeutics INC. | $16.84 | 2023 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.